Parathyroid cancer: Etiology, clinical presentation and treatment

Franco Lumachi, S. M M Basso, Umberto Basso

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Parathyroid carcinoma (PC) is an uncommon finding, accounting for only 1-2% of patients with primary hyperparathyroidism (HPT), but a relatively higher incidence has been reported in Italy and Japan. The etiology of the tumour remains unclear, but molecular analysis studies have hypothesised the involvement of mutations of several genes in the pathogenesis of PC, including the oncogene cyclin D1 or PRAD1 located at the chromosome 13, the retinoblastoma and the p53 tumour suppressor gene. The clinical presentation of patients with PC is mainly related to the increased secretion of PTH rather than to the tumour burden. The pre-operative diagnosis of malignancy is very difficult to obtain, and, thus, intra-operative recognition of PC is mandatory. However, reliable signs of malignancy are rarely detectable. Probably, only vascular invasion, that correlates with tumour recurrence and metastases, should be considered useful in confirming malignancy, although both Ki-67 and Cyclin D1 have been recently used to aid in the definitive diagnosis. The en bloc resection of the tumour, together with ipsilateral thyroid lobe and adjacent structures, only if involved, avoiding any capsular rupture of the mass, represents the gold standard of surgical treatment of patients. Although the PC has traditionally been considered as a radioresistant tumour, there are some retrospective data holding a possible benefit from postoperative irradiation. No cytotoxic regimen with proven efficacy is currently available for patients with PC, but since hypercalcemia is ultimately the most frequent cause of death, several studies have suggested the usefulness of bisphosphonates (i.e., clodronate, pamidronate and zoledronate), calcitonin, and calcimimetic agents (i.e., cinacalcet) in patients with PC and severe hypercalcemia. In conclusion, PC is a rare malignancy and the NCDB survey reports an overall five- and ten-year survival rate of 85% and 49%, respectively. However, it is very difficult to predict the clinical behaviour of patients with PC and probably the ultimate prognosis depends on successful resection of the tumour at the initial surgery.

Original languageEnglish
Pages (from-to)4803-4807
Number of pages5
JournalAnticancer Research
Volume26
Issue number6 C
Publication statusPublished - Nov 2006

Fingerprint

Parathyroid Neoplasms
Neoplasms
Therapeutics
pamidronate
zoledronic acid
Cyclin D1
Hypercalcemia
Calcimimetic Agents
Clodronic Acid
Chromosomes, Human, Pair 13
Primary Hyperparathyroidism
Retinoblastoma
Diphosphonates
Calcitonin
Tumor Burden
Tumor Suppressor Genes
Oncogenes
Italy
Blood Vessels
Rupture

Keywords

  • Bisphosphonates
  • Hypercalcemia
  • Parathyroid cancer
  • Parathyroid carcinoma
  • Primary hyperparathyroidism
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Parathyroid cancer : Etiology, clinical presentation and treatment. / Lumachi, Franco; Basso, S. M M; Basso, Umberto.

In: Anticancer Research, Vol. 26, No. 6 C, 11.2006, p. 4803-4807.

Research output: Contribution to journalArticle

Lumachi, F, Basso, SMM & Basso, U 2006, 'Parathyroid cancer: Etiology, clinical presentation and treatment', Anticancer Research, vol. 26, no. 6 C, pp. 4803-4807.
Lumachi, Franco ; Basso, S. M M ; Basso, Umberto. / Parathyroid cancer : Etiology, clinical presentation and treatment. In: Anticancer Research. 2006 ; Vol. 26, No. 6 C. pp. 4803-4807.
@article{714b5cbef43c41ceb3562ff47eb43ee6,
title = "Parathyroid cancer: Etiology, clinical presentation and treatment",
abstract = "Parathyroid carcinoma (PC) is an uncommon finding, accounting for only 1-2{\%} of patients with primary hyperparathyroidism (HPT), but a relatively higher incidence has been reported in Italy and Japan. The etiology of the tumour remains unclear, but molecular analysis studies have hypothesised the involvement of mutations of several genes in the pathogenesis of PC, including the oncogene cyclin D1 or PRAD1 located at the chromosome 13, the retinoblastoma and the p53 tumour suppressor gene. The clinical presentation of patients with PC is mainly related to the increased secretion of PTH rather than to the tumour burden. The pre-operative diagnosis of malignancy is very difficult to obtain, and, thus, intra-operative recognition of PC is mandatory. However, reliable signs of malignancy are rarely detectable. Probably, only vascular invasion, that correlates with tumour recurrence and metastases, should be considered useful in confirming malignancy, although both Ki-67 and Cyclin D1 have been recently used to aid in the definitive diagnosis. The en bloc resection of the tumour, together with ipsilateral thyroid lobe and adjacent structures, only if involved, avoiding any capsular rupture of the mass, represents the gold standard of surgical treatment of patients. Although the PC has traditionally been considered as a radioresistant tumour, there are some retrospective data holding a possible benefit from postoperative irradiation. No cytotoxic regimen with proven efficacy is currently available for patients with PC, but since hypercalcemia is ultimately the most frequent cause of death, several studies have suggested the usefulness of bisphosphonates (i.e., clodronate, pamidronate and zoledronate), calcitonin, and calcimimetic agents (i.e., cinacalcet) in patients with PC and severe hypercalcemia. In conclusion, PC is a rare malignancy and the NCDB survey reports an overall five- and ten-year survival rate of 85{\%} and 49{\%}, respectively. However, it is very difficult to predict the clinical behaviour of patients with PC and probably the ultimate prognosis depends on successful resection of the tumour at the initial surgery.",
keywords = "Bisphosphonates, Hypercalcemia, Parathyroid cancer, Parathyroid carcinoma, Primary hyperparathyroidism, Review",
author = "Franco Lumachi and Basso, {S. M M} and Umberto Basso",
year = "2006",
month = "11",
language = "English",
volume = "26",
pages = "4803--4807",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - Parathyroid cancer

T2 - Etiology, clinical presentation and treatment

AU - Lumachi, Franco

AU - Basso, S. M M

AU - Basso, Umberto

PY - 2006/11

Y1 - 2006/11

N2 - Parathyroid carcinoma (PC) is an uncommon finding, accounting for only 1-2% of patients with primary hyperparathyroidism (HPT), but a relatively higher incidence has been reported in Italy and Japan. The etiology of the tumour remains unclear, but molecular analysis studies have hypothesised the involvement of mutations of several genes in the pathogenesis of PC, including the oncogene cyclin D1 or PRAD1 located at the chromosome 13, the retinoblastoma and the p53 tumour suppressor gene. The clinical presentation of patients with PC is mainly related to the increased secretion of PTH rather than to the tumour burden. The pre-operative diagnosis of malignancy is very difficult to obtain, and, thus, intra-operative recognition of PC is mandatory. However, reliable signs of malignancy are rarely detectable. Probably, only vascular invasion, that correlates with tumour recurrence and metastases, should be considered useful in confirming malignancy, although both Ki-67 and Cyclin D1 have been recently used to aid in the definitive diagnosis. The en bloc resection of the tumour, together with ipsilateral thyroid lobe and adjacent structures, only if involved, avoiding any capsular rupture of the mass, represents the gold standard of surgical treatment of patients. Although the PC has traditionally been considered as a radioresistant tumour, there are some retrospective data holding a possible benefit from postoperative irradiation. No cytotoxic regimen with proven efficacy is currently available for patients with PC, but since hypercalcemia is ultimately the most frequent cause of death, several studies have suggested the usefulness of bisphosphonates (i.e., clodronate, pamidronate and zoledronate), calcitonin, and calcimimetic agents (i.e., cinacalcet) in patients with PC and severe hypercalcemia. In conclusion, PC is a rare malignancy and the NCDB survey reports an overall five- and ten-year survival rate of 85% and 49%, respectively. However, it is very difficult to predict the clinical behaviour of patients with PC and probably the ultimate prognosis depends on successful resection of the tumour at the initial surgery.

AB - Parathyroid carcinoma (PC) is an uncommon finding, accounting for only 1-2% of patients with primary hyperparathyroidism (HPT), but a relatively higher incidence has been reported in Italy and Japan. The etiology of the tumour remains unclear, but molecular analysis studies have hypothesised the involvement of mutations of several genes in the pathogenesis of PC, including the oncogene cyclin D1 or PRAD1 located at the chromosome 13, the retinoblastoma and the p53 tumour suppressor gene. The clinical presentation of patients with PC is mainly related to the increased secretion of PTH rather than to the tumour burden. The pre-operative diagnosis of malignancy is very difficult to obtain, and, thus, intra-operative recognition of PC is mandatory. However, reliable signs of malignancy are rarely detectable. Probably, only vascular invasion, that correlates with tumour recurrence and metastases, should be considered useful in confirming malignancy, although both Ki-67 and Cyclin D1 have been recently used to aid in the definitive diagnosis. The en bloc resection of the tumour, together with ipsilateral thyroid lobe and adjacent structures, only if involved, avoiding any capsular rupture of the mass, represents the gold standard of surgical treatment of patients. Although the PC has traditionally been considered as a radioresistant tumour, there are some retrospective data holding a possible benefit from postoperative irradiation. No cytotoxic regimen with proven efficacy is currently available for patients with PC, but since hypercalcemia is ultimately the most frequent cause of death, several studies have suggested the usefulness of bisphosphonates (i.e., clodronate, pamidronate and zoledronate), calcitonin, and calcimimetic agents (i.e., cinacalcet) in patients with PC and severe hypercalcemia. In conclusion, PC is a rare malignancy and the NCDB survey reports an overall five- and ten-year survival rate of 85% and 49%, respectively. However, it is very difficult to predict the clinical behaviour of patients with PC and probably the ultimate prognosis depends on successful resection of the tumour at the initial surgery.

KW - Bisphosphonates

KW - Hypercalcemia

KW - Parathyroid cancer

KW - Parathyroid carcinoma

KW - Primary hyperparathyroidism

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=33845960106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845960106&partnerID=8YFLogxK

M3 - Article

C2 - 17214344

AN - SCOPUS:33845960106

VL - 26

SP - 4803

EP - 4807

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -